The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received 4 analyst ratings in the last quarter, with 1 being bullish and 3 somewhat bullish. The average price target is $95.25, significantly higher than the current price of $35.68. The average price target has increased by 0.26% over the past month.
October 10, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has received positive analyst ratings, which could potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can drive stock prices. In this case, Ultragenyx Pharmaceutical has received mostly positive ratings, which could make the stock more attractive to investors and potentially drive the price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100